MRK250103P90000
- 0.02
- 0.000.00%
Merck & Co Newsroom
Express News | Merck China: Chinese National Medical Products Administration Has Approved Hpv Vaccine for Men
CICC: Maintains WUXI BIO 'Outperform Industry' rating, Target Price reduced to HKD 19.09.
CICC released a research report stating that it raised the Target Price for WUXI BIO (02269) by 15% to HKD 19.09, maintaining an "outperform the Industry" rating. The profit forecasts for 2024 and 2025 remain unchanged, and profit forecasts for 2026 have been introduced for the first time, amounting to 4.693 billion RMB. WUXI BIO announced that its Irish vaccine factory has reached an agreement with Merck (MSD International GmbH), whereby Merck will acquire WUXI BIO's vaccine factory in Ireland, with a total transaction value of approximately USD 0.5 billion. The company expects this transaction to complete in the first half of 2026, satisfying customary closing conditions.
Express News | Merck's Gardasil has become the first and currently the only HPV vaccine approved for use in males in China.
Truist Financial Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $110
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Unpacking the Latest Options Trading Trends in Merck & Co
Merck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million
Merck & Compnay and OPKO Health Shares Are Trading Higher After the Companies Announced a License and Collaboration Agreement to Develop an Epstein-Barr Virus Vaccine.
OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck
IBM, Walt Disney Share Gains Lead Dow's 167-Point Jump
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Express News | Modex Therapeutics- Development Triggers Undisclosed Milestone Payment From Merck
Express News | OPKO Health’s Modex Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration With Merck
Express News | CITIC Securities: Upgraded WUXI BIO's Target Price to HKD 19.09, maintaining an "Outperform Industry" rating.
Express News | Citi: The sale of the Irish vaccine facility by WUXI BIO will have no negative impact on finances and will improve overall profitability.
Express News | WUXI BIO responded to the sale of the Ireland vaccine factory for 0.5 billion USD.
Merck Lanza La Primera Plataforma De Confianza Ciberfísica En El Mercado
Merck Lance La Première Plateforme De Confiance Cyber-physique Sur Le Marché Pour Résoudre Les Problèmes De Sécurité Des Produits Et De Contrefaçon
Merck Führt Erste Cyber-physische Digital-Trust-Plattform Für Höhere Produktsicherheit Und Schutz Vor Produktfälschung Am Markt Ein
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million